Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2

Bioorganic & Medicinal Chemistry
2009.0

Abstract

Endogenous mu-opioid receptor (MOR) selective peptides, endomorphin-1 (EM-1) and endomorphin-2 (EM-2), unlike so called 'typical opioids', are characterized by the presence of Pro(2) residue, which is a spacer connecting aromatic pharmacophoric residues. In order to investigate structural requirements for position 2, we synthesized endomorphin analogs incorporating, instead of Pro, unnatural amino acids with six-membered heterocyclic rings, such as piperidine 2-, 3- or 4-carboxylic acids (Pip, Nip and Inp, respectively). (R)-Nip residue turned out to be favourable for improving MOR affinity. Introduction of 2',6'-dimethyltyrosine (Dmt) instead of Tyr(1) led to obtaining [Dmt(1), (R)-Nip(2)]EM-2 which showed exceptional MOR affinity and high stability against enzymatic degradation in rat brain homogenate. In in vivo hot-plate test in mice, this analog given intracerebroventicularly (i.c.v.), produced profound supraspinal analgesia, being much more potent than EM-2. The antinociceptive effect of this analog lasted about 170 min and was almost completely reversed by beta-funaltrexamine (beta-FNA), a selective MOR antagonist.

Knowledge Graph

Similar Paper

Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2
Bioorganic & Medicinal Chemistry 2009.0
Novel highly potent μ-opioid receptor antagonist based on endomorphin-2 structure
Bioorganic & Medicinal Chemistry Letters 2008.0
Hybrid peptides endomorphin-2/DAMGO: Design, synthesis and biological evaluation
European Journal of Medicinal Chemistry 2013.0
Synthesis and Characterization of Potent and Selective μ-Opioid Receptor Antagonists, [Dmt, <scp>d</scp>-2-Nal<sup>4</sup>]endomorphin-1 (Antanal-1) and [Dmt<sup>1</sup>, <scp>d</scp>-2-Nal<sup>4</sup>]endomorphin-2 (Antanal-2)
Journal of Medicinal Chemistry 2007.0
Design, synthesis, and biological activity of new endomorphin analogs with multi-site modifications
Bioorganic &amp; Medicinal Chemistry 2020.0
Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues as Extremely Potent μ-Opioid Agonists
Journal of Medicinal Chemistry 2013.0
Synthesis of Mixed Opioid Affinity Cyclic Endomorphin-2 Analogues with Fluorinated Phenylalanines
ACS Medicinal Chemistry Letters 2015.0
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity
Bioorganic &amp; Medicinal Chemistry 2014.0
The Effect of Pro<sup>2</sup> Modifications on the Structural and Pharmacological Properties of Endomorphin-2
Journal of Medicinal Chemistry 2012.0
Synthesis and binding activity of endomorphin-1 analogues containing β-amino acids
Bioorganic &amp; Medicinal Chemistry Letters 2000.0